Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis

FinADASpA Study Grp, J. Hiltunen, P. Parmanne, T. Sokka, T. Lamberg, P. Isomäki, O. Kaipiainen-Seppänen, R. Peltomaa, T. Uutela, L. Pirila, K. Taimen, M. J. Kauppi, T. Yli-Kerttula, R. Tuompo, H. Relas, S. Kortelainen, K. Paalanen, J. Asikainen, P. Ekman, A. SantistebanK-L Vidqvist, K. Tadesse, M. Romu, J. Borodina, P. Elfving, H. Valleala, M. Leirisalo-Repo, Minna Rantalaiho, H. Kautiainen, T. S. Jokiranta, K. K. Eklund

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalRheumatology International
Volume42
Pages (from-to)1015–1025
Number of pages11
ISSN0172-8172
DOIs
Publication statusPublished - 2022
MoE publication typeA1 Journal article-refereed

Fields of Science

  • Spondyloarthritis
  • Ankylosing spondylitis
  • Biological therapy
  • Anti-drug antibodies
  • Disease activity
  • Therapeutic drug monitoring
  • MODIFYING ANTIRHEUMATIC DRUGS
  • LONG-TERM TREATMENT
  • ANKYLOSING-SPONDYLITIS
  • RHEUMATOID-ARTHRITIS
  • ANTIDRUG ANTIBODIES
  • DISEASE-ACTIVITY
  • INFLIXIMAB TREATMENT
  • CERTOLIZUMAB PEGOL
  • ALPHA BLOCKERS
  • DOUBLE-BLIND
  • 3121 General medicine, internal medicine and other clinical medicine

Cite this